- The Influence of Sleep Apnea on 24-hour and Nocturnal ECG and Blood Pressure Parameters in Patients with Acute Heart Failure. [Journal Article]
- MPMed Princ Pract 2018 Dec 11
- CONCLUSIONS: The presence of significant sleep apnea was found to influence the blood pressure values and nocturnal ventricular ectopy in patients with stabilized AHF. Sleep apnea, 24-hour ECG and blood pressure monitoring could provide important information with potential impact on patient management.
- Renal Functions and Prognosis Stratification in Chronic Heart Failure Patients and the Importance of Neutrophil Gelatinase-Associated Lipocalin. [Journal Article]
- KBKidney Blood Press Res 2018 Dec 07; 43(6):1865-1877
- CONCLUSIONS: The findings of the study showed that NGAL associated with NT-proBNP was a stronger predictor of the primary endpoint than NGAL or NT-proBNP alone. The level of NGAL was rising in hypertension, ischemia, anemia, hypoalbuminemia, diabetes or arrhythmias.
- Nomogram Model to Predict Cardiorenal Syndrome Type 1 in Patients with Acute Heart Failure. [Journal Article]
- KBKidney Blood Press Res 2018 Dec 07; 43(6):1832-1841
- CONCLUSIONS: The proposed nomogram could predict the individualized risk of CRS1 with good accuracy, high discrimination, and potential clinical applicability in patients with AHF.
- Developing a quality standard for verbal communication during CABG procedures. [Journal Article]
- STSemin Thorac Cardiovasc Surg 2018 Dec 08
- CONCLUSIONS: In this study, a list was developed containing 64 items that practitioners unanimously considered critical to verbalize during a CABG procedure. It forms the foundation of a quality standard for verbal communication during cardio-pulmonary bypass (CPB) and can increase safety and efficiency of cardiac surgery.
- Toward a solution for cardiac failure in the newborn. [Journal Article]
- XXenotransplantation 2018 Dec 11; :e12479
- The newborn infant with severe cardiac failure owed to congenital structural heart disease or cardiomyopathy poses a daunting therapeutic challenge. The ideal solution for both might be cardiac trans...
The newborn infant with severe cardiac failure owed to congenital structural heart disease or cardiomyopathy poses a daunting therapeutic challenge. The ideal solution for both might be cardiac transplantation if availability of hearts was not limiting and if tolerance could be induced, obviating toxicity of immunosuppressive therapy. If one could safely and effectively exploit neonatal tolerance for successful xenotransplantation of the heart, the challenge of severe cardiac failure in the newborn infant might be met. We discuss the need, the potential for applying neonatal tolerance in the setting of xenotransplantation and the possibility that other approaches to this problem might emerge.
- The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. [Journal Article]
- EJEur J Heart Fail 2018 Dec 10
- CONCLUSIONS: TnT is elevated to a greater extent in heart failure patients with diabetes compared to those without (whereas NT-proBNP is not). TnT and NT-proBNP are additive in predicting risk and when combined help identify diabetes patients at extremely high absolute risk.
- Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges. [Review]
- EJEur J Heart Fail 2018 Dec 10
- Multiple drug classes have shown incremental benefits in heart failure with reduced ejection fraction. Most of these trials were designed to achieve specific doses of the investigational agent. Clini...
Multiple drug classes have shown incremental benefits in heart failure with reduced ejection fraction. Most of these trials were designed to achieve specific doses of the investigational agent. Clinical practice guidelines recommend using the same target dosing of therapies, as tolerated. However, with the increasing number of available therapies, clinicians face the challenge of simultaneously using several drugs, achieving target doses, and managing side effects that are often overlapping. Blood pressure, renal function, hyperkalaemia, and other factors may impede achieving target doses of all medications, leaving clinicians with dilemmas as to how to sequence and dose these various classes of drugs. The guideline-directed eligibility for certain drugs and devices requires stability on maximally tolerated doses of background therapies. However, significant variability exists in dosing achieved in clinical practice. We discuss the existing background data regarding the doses of heart failure medications in clinical trials and in practice, and provide recommendations on how to navigate this complex therapeutic decision-making.
- Implantable cardiac defibrillators for people with non-ischaemic cardiomyopathy. [Review]
- CDCochrane Database Syst Rev 2018 Dec 08; 12:CD012738
- CONCLUSIONS: The use of ICD in addition to medical therapy in people with non-ischaemic cardiomyopathy decreases all-cause mortality and sudden cardiac deaths and probably decreases mortality from cardiovascular causes compared to medical therapy alone. Their use probably increases the risk for adverse events. However, these devices come at a high cost, and shocks from ICDs cause a deterioration in quality of life.
- Remote monitoring of implantable cardioverter defibrillators: Patient experiences and preferences for follow-up. [Journal Article]
- PCPacing Clin Electrophysiol 2018 Dec 10
- CONCLUSIONS: In general, patients were highly satisfied with RPM, but a subgroup preferred in-clinic follow-up. Therefore, physicians should include patients' concerns and preferences in the decision-making process, to tailor device follow-up to individual patients' needs and preferences. This article is protected by copyright. All rights reserved.
New Search Next
- Cardio-renal protective effect of SGLT2 inhibitors and mitochondrial function. [Editorial]
- JDJ Diabetes Investig 2018 Dec 09
- Cardio-renal protective effect of Sodium Glucose Co-transporter-2 (SGLT2) inhibitors is well established by three large clinical trials; Empagliflozin, Cardiovascular Outcome Events Trial in Type 2 D...
Cardio-renal protective effect of Sodium Glucose Co-transporter-2 (SGLT2) inhibitors is well established by three large clinical trials; Empagliflozin, Cardiovascular Outcome Events Trial in Type 2 Diabetes Patients (EMPA-REG OUTCOME), Canagliflozin Cardiovascular Assessment Study (CANVAS), and most recently Dapagliflozin Effect on Cardiovascular Events Trial 58 by the Thrombolysis in Myocardial Infarction Study Group (DECLARE-TIMI 58). Three different SGLT2 inhibitors, empagliflozin, canagliflozin and dapagliflozin, were proven effective not only for their glucose lowering effect, but in reducing deterioration of renal function and prevented hospitalization due to heart failure. This article is protected by copyright. All rights reserved.